Knight Therapeutics commits $1 mln to Genesys Ventures III
Canadian specialty pharmaceutical company Knight Therapeutics Inc (TSX: GUD) has committed $1 million to Genesys Ventures III, the third life sciences fund of Canadian venture capital firm Genesys Capital. Montréal-based Knight said the investment, made as part of a $130 million strategy, is its eighth in a life sciences fund. PE Hub Canada reported this week that Genesys raised $90 million in the initial close of Fund III, which is targeted to raise $125 million in total. Other disclosed fund investors include the Fonds de solidarité FTQ and HarbourVest Canada Growth Fund.
18 August 2016•3 mins read
